Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRA-9620 oral insulin in infants with short bowel syndrome
NL-OMON45489Phase 2Withdrawn
- Sponsor
- Nutrinia
- Start
- Feb 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NTRA-9620 in short bowel syndrome (SBS) (3 arms), sponsored by Nutrinia. Primary endpoints: Percent change in percent parenteral nutrition from baseline to 12 weeks and Percent change in percent parenteral nutrition from baseline to 24 weeks. Planned start Feb 2017; status: withdrawn.
02
Drugs
NTRA-9620
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON45489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45489.